TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Metrics to compare | TCRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTCRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.5x | −3.2x | −0.5x | |
PEG Ratio | −0.04 | −0.15 | 0.00 | |
Price / Book | 0.5x | 2.6x | 2.6x | |
Price / LTM Sales | 6.1x | 10.3x | 3.2x | |
Upside (Analyst Target) | - | 293.5% | 47.6% | |
Fair Value Upside | Unlock | 10.5% | 6.1% | Unlock |